Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Ravi K. Goyal, Gebra Cuyun Carter, Saurabh P. Nagar, Emily Nash Smyth, Gregory L. Price, Rohan C. Parikh, Yu-Jing Huang, Li Li, Keith L. Davis & James A. Kaye. (2021) Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 699-710.
Read now
Read now
Sun-Kyeong Park, Jae-A Park, So-Young Yang, Ju-Young Shin & Hyein Koh. (2020) The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data. Current Medical Research and Opinion 36:11, pages 1825-1833.
Read now
Read now
Shaheenah Dawood, Joanne Wing-yan Chiu, Chiun-Sheng Huang, Shona Nag, Aumkhae Sookprasert, Yoon-Sim Yap & Mastura Md Yusof. (2020) Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. Current Medical Research and Opinion 36:8, pages 1363-1373.
Read now
Read now
Benjamin Walbaum, Francisco Acevedo, Lidia Medina, M. Loreto Bravo, Tomas Merino, Mauricio Camus, Francisco Dominguez, Sebastian Mondaca, Hector Galindo, Bruno Nervi, Carolina Ibañez, Jorge Madrid, Jose Peña, Erica Koch, Marcelo Garrido, Mauricio P. Pinto & César Sánchez. (2020) First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution. Current Medical Research and Opinion 36:7, pages 1195-1199.
Read now
Read now
Ravi K. Goyal, Gebra Cuyun Carter, Saurabh P. Nagar, Emily N. Smyth, Gregory L. Price, Yu-Jing Huang, Li Li, Keith L. Davis & James A. Kaye. (2019) Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2− metastatic breast cancer. Current Medical Research and Opinion 35:10, pages 1699-1710.
Read now
Read now
Derek H. Tang, Nanxin Li, Ella X. Du, Miranda Peeples, Lihao Chu, Jipan Xie & Victoria Barghout. (2017) First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study. Current Medical Research and Opinion 33:12, pages 2137-2143.
Read now
Read now
Nanxin Li, Ella X. Du, Lihao Chu, Miranda Peeples, Jipan Xie, Victoria Barghout & Derek H. Tang. (2017) Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. Expert Opinion on Pharmacotherapy 18:12, pages 1167-1178.
Read now
Read now
Annie Guérin, Yanni Hao, Derek Tang, Miranda Peeples, Anna Fang, Andrew Kageleiry, Valerie Koo, Nanxin Li & Eric Q. Wu. (2016) Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opinion on Pharmacotherapy 17:9, pages 1189-1196.
Read now
Read now
Nanxin Li, Yanni Hao, Valerie Koo, Anna Fang, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. Journal of Medical Economics 19:4, pages 414-423.
Read now
Read now
Nanxin Li, Yanni Hao, Andrew Kageleiry, Miranda Peeples, Anna Fang, Valerie Koo, Eric Q. Wu & Annie Guérin. (2016) Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Current Medical Research and Opinion 32:2, pages 385-394.
Read now
Read now
Peggy L Lin, Yanni Hao, Jipan Xie, Nanxin Li, Erika Ohashi, Valerie Koo & Eric Q Wu. (2015) Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opinion on Pharmacotherapy 16:14, pages 2101-2111.
Read now
Read now
Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo, James E. Signorovitch, Eric Q. Wu & Denise A. Yardley. (2015) Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2− metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Current Medical Research and Opinion 31:6, pages 1095-1103.
Read now
Read now
Articles from other publishers (44)
Layal Al Mahmasani, Ghid Amhaz, Reine Abou Zeidane, Nathalie Chamseddine, Taha Hatab, Saad Sabbagh, Maya Charafeddine & Hazem I. Assi. (2023) Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer. Frontiers in Oncology 13.
Crossref
Crossref
Luis Fein, Nicolas Lazaretti, Yamil López Chuken, J. Rogelio González Ramírez Benfield, Max S. Mano, Jose Lobaton, Ernesto Korbenfeld, Fernanda Damian, Dongrui R. Lu, Ave Mori, Shem J. Patyna & Sandra Franco. (2023) Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation.
Crossref
Crossref
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm & Andreas Schneeweiss. (2023) Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register. Senologie - Zeitschrift für Mammadiagnostik und -therapie 20:01, pages 43-56.
Crossref
Crossref
Ignacio Robledo Salas, Florencia Guerra, Lorena Boixadera, María Mateo, Pablo Cresta Morgado, Andrea Aguilar & Valeria Cáceres. (2022) Terapia endocrina para el cáncer de MAMA RH+/HER2- avanzado/metastásico en Argentina. Oncología Clínica 27:1.
Crossref
Crossref
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm & Andreas Schneeweiss. (2022) Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe und Frauenheilkunde 82:10, pages 1055-1067.
Crossref
Crossref
Zhe-Yu Hu, Yu Tang, Liping Liu, Ning Xie, Can Tian, Binliang Liu, Lixin Zou, Wei Zhou, Yikai Wang, Xuefeng Xia & Quchang Ouyang. (2022) Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study. eClinicalMedicine 51, pages 101567.
Crossref
Crossref
Qiuyue Liu, Juan Qiu, Qianrun Lu, Yujin Ma, Shu Fang, Bing Bu & Lihua Song. (2022) Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study. Frontiers in Oncology 12.
Crossref
Crossref
Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova & Xavier Pivot. (2022) The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer 22:3, pages 223-234.
Crossref
Crossref
Yiqun Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma & Binghe Xu. (2022) Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. The Breast 61, pages 129-135.
Crossref
Crossref
Kwang Hyun Choi, Chan Sub Park, Sang Hee Kim, Na Won Kim, Ju Hyeon Lee, Ji Yea Kim, In Chul Park, Min Ki Seong, Hyun-Ah Kim & Woo Chul Noh. (2021) Comparison of the Efficacy between First-Line Treatment Regimens for Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer. Journal of Breast Disease 9:2, pages 65-70.
Crossref
Crossref
Carlos Barrios, Ruffo Freitas-Junior, Sandro Martins, Jose Bines, Maria Del Pilar Estevez-Diz & Maira Caleffi. (2021) Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology:7, pages 474-485.
Crossref
Crossref
Jennifer L. Caswell-Jin, Alison Callahan, Natasha Purington, Summer S. Han, Haruka Itakura, Esther M. John, Douglas W. Blayney, George W. SledgeJrJr, Nigam H. Shah & Allison W. Kurian. (2021) Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics:5, pages 600-614.
Crossref
Crossref
Gustavo Werutsky, Tomás Reinert, Mahira Lopes Rosa & Carlos Henrique Barrios. (2021) Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors. Clinical Breast Cancer 21:6, pages e688-e692.
Crossref
Crossref
Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang & Binghe Xu. (2021) Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Frontiers in Oncology 10.
Crossref
Crossref
Chris Twelves, Sue Cheeseman, Will Sopwith, Matthew Thompson, Majid Riaz, Necibe Ahat-Donker, Melissa Myland, Adam Lee, Raymond Przybysz, Stuart Turner, Geoff Hall & Tim Perren. (2020) Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer 20:1.
Crossref
Crossref
Soohyeon Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh & Yeon Hee Park. (2020) Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers 12:11, pages 3265.
Crossref
Crossref
Gabrielle B. Rocque, Aidan Gilbert, Courtney P. Williams, Kelly M. Kenzik, Arie Nakhmani, Pravinkumar G. Kandhare, Smita Bhatia, Mark E. Burkard & Andres Azuero. (2020) Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. JCO Clinical Cancer Informatics:4, pages 500-513.
Crossref
Crossref
Gabrielle B. Rocque, Pravinkumar G. Kandhare, Courtney P. Williams, Arie Nakhmani, Andres Azuero, Mark E. Burkard, Andres Forero, Smita Bhatia & Kelly M. Kenzik. (2020) Visualization of Sequential Treatments in Metastatic Breast Cancer. JCO Clinical Cancer Informatics:4, pages 1-8.
Crossref
Crossref
Julien Simon, Marie Chaix, Oumar Billa, Ariane Mamguem Kamga, Patrick Roignot, Sylvain Ladoire, Charles Coutant, Patrick Arveux, Catherine Quantin & Tienhan Sandrine Dabakuyo-Yonli. (2020) Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study. British Journal of Cancer 123:7, pages 1071-1077.
Crossref
Crossref
Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang & Qiang Liu. (2020) Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. The Oncologist 25:8, pages e1170-e1180.
Crossref
Crossref
Athanasios Kotsakis, Alexandros Ardavanis, Georgios Koumakis, Epameinondas Samantas, Amanta Psyrri & Christos Papadimitriou. (2019) Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study. BMC Cancer 19:1.
Crossref
Crossref
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im, HK Ahn, EK Cho, IH Park, KS Lee, SS Sim, SJ Hong, MH Chang, JH Kim, YJ Kim, SH Kim, KJ Suh, YH Park, WY Park, YL Choi, JH Yu, YH Im, JS Ahn, JY Hur, SH Park, JY Kim, SJ Nam, JE Lee, SW Kim, SK Lee, SA Im, MS Kim, TY Kim, DY Oh, TY Kim, KH Lee, DW Lee, HJ Kim, KH Jung, SB Kim, JH Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, KE Lee, HJ Kim, MH Lee, JH Cho & JH Lim. (2019) Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology 20:12, pages 1750-1759.
Crossref
Crossref
Olivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, Marc Debled, Paul H. Cottu, Barbara Pistilli, Laurence Vanlemmens, Marianne Leheurteur, Christelle Lévy, Lilian Laborde, Lionel Uwer, Veronique D'hondt, Delphine Berchery, Veronique Lorgis, Jean-Marc Ferrero, Genevieve Perrocheau, Coralie Courtinard, Marie Ange Mouret-Reynier, Michel Velten, Mathias Breton, Damien Parent, Sylvie Chabaud, Mathieu Robain & Thomas Bachelot. (2019) Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. European Journal of Cancer 118, pages 131-141.
Crossref
Crossref
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, Arshi Denton, Simon Waters, Ailsa Sita-Lumsden, Farah Rehman, Chara Stavraka, Hartmut Kristeleit, Elinor Sawyer, David Houghton, Neville Davidson, Sacha Howell, Julia Choy, Peter Harper, Rebecca Roylance, Raja Fharat, Kabir Mohammed, Alistair Ring & Stephen Johnston. (2019) Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment 174:3, pages 731-740.
Crossref
Crossref
Alison Palumbo, Gary Lau & Megan Saraceni. (2018) Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer. Annals of Pharmacotherapy 53:2, pages 178-185.
Crossref
Crossref
Anand A. Dalal, Geneviève Gauthier, Patrick Gagnon-Sanschagrin, Rebecca Burne, Annie Guérin, Polly Niravath & Tania Small. (2018) Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer. Advances in Therapy 35:9, pages 1356-1367.
Crossref
Crossref
Samantha K. Kurosky, Debanjali Mitra, Giovanni Zanotti & James A. Kaye. (2018) Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2− Breast Cancer: A Multicountry Retrospective Medical Record Review. Clinical Breast Cancer 18:4, pages e529-e538.
Crossref
Crossref
Deborah Goldschmidt, Anand A. Dalal, Hela Romdhani, Sneha Kelkar, Annie Guerin, Genevieve Gauthier, Eric Q. Wu, Polly Niravath & Tania Small. (2018) Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. Advances in Therapy 35:4, pages 482-493.
Crossref
Crossref
Gül A. Başaran, Chris Twelves, Véronique Diéras, Javier Cortés & Ahmad Awada. (2018) Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews 63, pages 144-155.
Crossref
Crossref
Monika Parisi, Corey Pelletier, Dasha Cherepanov & Michael S Broder. (2018)
Outcomes research examining treatments, quality of life and costs in
HER2
-negative and triple-negative metastatic breast cancer: a systematic literature review
. Journal of Comparative Effectiveness Research 7:1, pages 67-83.
Crossref
Crossref
Giovanni Zanotti, Matthias Hunger, Julia J Perkins, Ruslan Horblyuk & Monique Martin. (2017) Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States. BMC Cancer 17:1.
Crossref
Crossref
Junichiro Watanabe, T. Hayashi, Y. Tadokoro, S. Nishimura & K. Takahashi. (2017) Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Research and Treatment 166:3, pages 911-917.
Crossref
Crossref
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A. Hudis, Joyce O'Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis & José Baselga. (2017) MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer. Clinical Cancer Research 23:17, pages 5218-5224.
Crossref
Crossref
Thomas Fietz, Hans Tesch, Jacqueline Rauh, Emil Boller, Lisa Kruggel, Martina Jänicke & Norbert Marschner. (2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study. The Breast 34, pages 122-130.
Crossref
Crossref
Paolo Marchetti, Nicolai Maass, Joseph Gligorov, Karin Berger, Finlay MacDougall, Jukka Montonen & Jan Lewis. (2017) Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective. The Breast 32, pages 247-255.
Crossref
Crossref
Marta Bonotto, Lorenzo Gerratana, Massimo Di Maio, Carmine De Angelis, Marika Cinausero, Stefano Moroso, Monica Milano, Brigida Stanzione, Piera Gargiulo, Donatella Iacono, Alessandro Marco Minisini, Mauro Mansutti, Gianpiero Fasola, Sabino De Placido, Grazia Arpino & Fabio Puglisi. (2017) Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. The Breast 31, pages 114-120.
Crossref
Crossref
Elżbieta Senkus & Aleksandra Łacko. (2017) Over-treatment in metastatic breast cancer. The Breast 31, pages 309-317.
Crossref
Crossref
Rita Caldeira & Mark Scazafave. (2016) Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States. Oncology and Therapy 4:2, pages 189-197.
Crossref
Crossref
Shinji Ohno. (2016) Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. Clinical Breast Cancer 16:4, pages 238-246.
Crossref
Crossref
Yanni Hao, Nanxin Li, Anna P. Fang, Valerie Koo, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy 33:6, pages 983-997.
Crossref
Crossref
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Valerie Koo, Erika Ohashi & Eric Q. Wu. (2016) Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2− mBC Patients With Multiple Metastatic Sites. Clinical Therapeutics 38:4, pages 905-917.
Crossref
Crossref
D.J.A. Lobbezoo, R.J.W. van Kampen, A.C. Voogd, M.W. Dercksen, F. van den Berkmortel, T.J. Smilde, A.J. van de Wouw, F.P.J. Peters, J.M.G.H. van Riel, N.A.J.B. Peters, M. de Boer, P.G.M. Peer & V.C.G. Tjan-Heijnen. (2016) In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Annals of Oncology 27:2, pages 256-262.
Crossref
Crossref
Uwe Güth, Dorothy Jane Huang, Andreas Schötzau & Seraina Margaretha Schmid. (2016) Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?. Oncology 90:1, pages 1-9.
Crossref
Crossref
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Valerie Koo, Erika Ohashi & Eric Q. Wu. (2015) Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. International Journal of Breast Cancer 2015, pages 1-9.
Crossref
Crossref